Robert S. Beil

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/80cb74e0-9197-11ed-85fe-8f01394d41e6.jpg

First Name

Robert

Last Name

Beil

NPI

1861585093

Faculty ID

7209

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Adult Medicine

Elsevier Profile

EMR ID

3968

Biography

<p>Robert Beil, MD, is Medical Director, CICERO Program, Medical Director, Montefiore Einstein Transgender Health Program and Co-Medical Director, Montefiore Einstein Prevention Program at Montefiore Einstein and Associate Professor at our Albert Einstein College of Medicine. As a General Internist, Dr. Beil has provided primary care to residents of the South Bronx for over 30 years. He has particular interest in HIV care and HIV prevention.</p><p>After receiving his Bachelor of Arts in biology 1988 from Washington University in St. Louis, Dr. Beil earned his Doctor of Medicine at the University of Cincinnati in 1993. He then came to Montefiore for his internship and residency in internal medicine from 1993 to 1996.</p><p>Dr. Beil's research focuses on HIV. He has been principal investigator on a number of research projects, and his work has been shared through numerous peer-reviewed publications and presentations.</p><p>Dr. Beil is board certified in Internal Medicine by the American Board of Internal Medicine, and is a Fellow of the American Academy of HIV Medicine. He has been listed as a Castle Connolly Top Doctor from 2015 until 2024.</p>

Is Open Scheduling

Off

Jessica M. Atrio

https://assets.montefioreeinstein.org/profiles/images/physphoto/Atrio_Jessica_M_MD_11119918.jpg

First Name

Jessica

Last Name

Atrio

NPI

1184882714

Faculty ID

13749

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Atrio is a board certified obstetrician gynecologist at Montefiore and Albert Einstein College of Medicine.&nbsp; She is a the Director of the Fellowship in Complex Family Planning, Vice Chair of Research and Clinical Teaching Professor for the Department of Obstetrics and Gynecology. She completed her undergraduate degree at Columbia University, medical degree at New York University, residency at Mount Sinai School of Medicine, as well as, a Masters of Science in Biostatistics and Epidemiology and a Family Planning Fellowship at the University of Southern California. She joined the Montefiore-Einstein faculty in 2013. She has a keen interest in translational research, contraception for medically complex patients, safe abortion provision, and the gynecologic care of HIV positive women. She is dedicated to patient advocacy and the optimization of safe patient outcomes.</p>

Research Profile

CHAM Provider

Off

Professional Title

Clinical Focus

&nbsp;Complex Family Planning

Research Focus

Dr. Atrio has a keen interest in translational research, contraception for medically complex patients, and the gynecologic care of HIV positive women.&nbsp;

Elsevier Profile

EMR ID

5722

Biography

<p>Jessica Maria Atrio, MD, MSc, is a board-certified obstetrician gynecologist and Associate Professor at Montefiore and Albert Einstein School of Medicine in the Department of Obstetrics &amp; Gynecology and Women&rsquo;s Health. Dr. Atrio is the Associate Vice Chair of Research, Associate Fellowship Director in Complex Family Planning, and a member of the Einstein Institutional Review Board.</p><p>Dr. Atrio graduated from Columbia University with her Bachelor of Arts in Psychology. She completed her Medical Degree at the New York University School of Medicine, residency at Mount Sinai School of Medicine as well as, a Masters of Science inBiostatistics and Epidemiology and a Family Planning Fellowship at the University of Southern California. She joined the Montefiore-Einstein faculty in 2013.</p><p>Dr. Atrio has a keen interest in translational research, contraception for medically complex patients, and the gynecologic care of HIV positive women. She is the author of many peer review publications and a reviewer for several academic journals. Her research has contributed to regional and international guidelines. She has received accolades and awards for her commitment to medical education and trainee mentorship. Dr. Atrio is the Principle Investigator for industry, grant and federally sponsored clinical investigations, including the <a href="https://www.nichd.nih.gov/research/supported/cctn&quot; target="_blank">Clinical Contraceptive Trial Network</a>. </p><p>Dr. Atrio serves on regional and national committees for professional societies and public health entities, including the New York State Department of Health, Society of Family Planning, and the American College of Obstetricians and Gynecologists. She is dedicated to patient advocacy and the optimization of safe patient outcomes.</p>

Is Open Scheduling

Off

Peter L. Alpert

https://assets.montefioreeinstein.org/profiles/images/physphoto/Alpert_Peter_MD_420x504.jpg

First Name

Peter

Last Name

Alpert

NPI

1104916907

Faculty ID

1967

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p style=" font-family: 'Times New Roman'; font-size: 12.0pt; margin-left: 0in; margin-right: 0in;">Clinical HIV studies</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

3858

Is Open Scheduling

Off

Matthew J. Akiyama

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/a703c590-85e5-11ec-a5a4-39080ebc53e5.jpg

First Name

Matthew

Last Name

Akiyama

NPI

1316259419

Faculty ID

14789

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Akiyama is an Associate Professor of Medicine and Clinician-Investigator in the Divisions of General Internal Medicine and Infectious Diseases. In addition to providing care and treatment to people living with HIV, hepatitis C virus (HCV), and substance use disorders, Dr. Akiyama conducts research focusing on HCV among socioeconomically marginalized populations with particular emphasis on the intersection of HCV in the criminal legal system and sub-Saharan Africa. Dr. Akiyama is the recipient of a K99/R00 award from the National Institute on Drug Abuse to develop and test an innovative strategy to improve linkage to and retention in HCV treatment among individuals recently released from jail. He is also the recipient of an Avenir Award from the National Institute on Drug Abuse focused on HCV Transmission Networks Among People Who Inject Drugs.&nbsp;</p>
<p>Dr. Akiyama&nbsp;completed his Infectious Diseases Fellowship at New York University/Bellevue Hospital Center and a Master of Science in Medical Anthropology at University College London in London, England.&nbsp;</p>
<p><strong>Selected Awards</strong>&nbsp;<strong>&amp; Honors</strong></p>
<p>Recipient, Justice Community Opioid Innovation Network LEAP Investigator Scholarship (2020)</p>
<p>Member, New York State Governor's Hepatitis C Elimination Task Force (2018)</p>
<p>Albert Einstein College of Medicine KL2 Career Development Award (2017)</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Provide care and treatment to people living with and at risk for HIV, viral hepatitis, and substance use disorders.<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Conduct research focusing on HIV and viral hepatitis.<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

Selected Publications

<div class="cit">
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><span style="font-family: Calibri, sans-serif;"><span style="font-size: 16px;"><strong>Akiyama MJ</strong>, Spaulding AC, Nijhawan AE.&nbsp;Long-Acting Injectable Antiretrovirals in Incarcerated Populations - Challenges and Opportunities.&nbsp;</span></span><span style="font-family: Calibri, sans-serif; font-size: 16px;">N Engl J Med. 2</span><span style="font-family: Calibri, sans-serif;"><span style="font-size: 16px;">022 Nov 10;387(19):1728-1730.</span></span></p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><strong>Akiyama MJ</strong>, Kronfli N, Cabezas J, Sheehan Y, Thurairajah PH, Lines R, Lloyd AR; International Network on Health and Hepatitis in Substance Users&ndash;Prisons Network.&nbsp;Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework.&nbsp;Lancet Gastroenterol Hepatol. 2021 May;6(5):391-400.&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><strong>Akiyama MJ</strong><span style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">, Muller A, Huang O, Lizcano J, Nyakowa M, Riback L, Ross J, Bundi H, Kulabi ES, Mwangi AM, Musyoki H, Cherutich P, Kurth A.</span> Hepatitis C-related knowledge, attitudes and perceived risk behaviours among people who inject drugs in Kenya: A qualitative study. <span style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">Glob Public Health. 2021 Mar 9:1-13.</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><strong>Akiyama MJ</strong>, Spaulding AC, Rich JD. Flattening the Curve for Incarcerated Populations - Covid-19 in Jails and Prisons. N Engl J Med.&nbsp;2020 May 28;382(22):2075-2077.&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><strong>Akiyama MJ</strong>, Lipsey D,^&nbsp;Ganova-Raeva L, Punkova L, Agyemang L, Sue A, Ramachandran S, Khudyakov Y, Litwin AH. A Phylogenetic Analysis of HCV Transmission, Relapse, and Reinfection Among People Who Inject Drugs Receiving Opioid Agonist Therapy.&nbsp;J Infect Dis. 2020 Mar 9.</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><strong>Akiyama MJ</strong>, Cleland CM, Lizcano J, Cherutich P, Kurth A. Hepatitis C Prevalence, Estimated Incidence, Risk Behaviors, and Genotypic Distribution Among People Who Inject Drugs Accessing Harm Reduction Services in Kenya: A Retrospective Cohort Study. Lancet ID.&nbsp;2019 Nov;19(11):1255-1263.</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><strong>Akiyama MJ</strong>, Columbus D, MacDonald R, Jordan AO, Schwartz J, Litwin AH, Eckhardt B, Carmody E.&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/31395019"><span style="color: black;">Linkage to hepatitis C care after incarceration in jail: a prospective, single arm clinical trial.</span></a>&nbsp;BMC Infect Dis. 2019 Aug 8;19(1):703.</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><strong>Akiyama MJ</strong>, Norton BL, Arnsten JH, Agyemang L, Heo M, Litwin AH.&nbsp;Intensive&nbsp;Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy.&nbsp;Annals of Internal Medicine.&nbsp;2019 Apr 9.</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">Spaulding AC, Graham CS,&nbsp;<strong>Akiyama MJ</strong>, Chhatwal J, Nijhawan AE, Ninburg MH, Rich JD, Strick LB, Taylor LE, Trooskin SB, Westergaard RP, Sabol WJ. HCV prevalence estimates among incarcerated persons.&nbsp;Hepatology. 2019 Apr 2.&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">Norton BL,&nbsp;<strong>Akiyama MJ</strong>, Zamor PJ, Litwin AH.&nbsp;Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice. Infect Dis Clin North Am. 2018 Jun;32(2):347-370.</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><strong>Akiyama MJ</strong>, Feffer R, Von Oehsen III WF, Litwin AH. Drug Purchasing Strategies to Treat People With Hepatitis C in the Criminal Justice System<strong>.&nbsp;</strong>AJPH. 2018 May;108(5):607-608.&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><strong>Akiyama MJ</strong>, Agyemang L, Arnsten, JH, Heo M, Norton BL, Schackman BR, Linas BP, Litwin AH.&nbsp;Rationale, design, and methodology of a trial evaluating three models of care for HCV treatment among injection drug users on opioid agonist therapy.&nbsp;BMC Infect Dis. 2018 Feb 9;18(1):74.&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">MacDonald R,&nbsp;<strong>Akiyama MJ</strong>, Kopolow A, Rosner Z, McGahee W, Joseph R, Jaffer M, Venters H. Full Title: Feasibility of Treating Hepatitis C in a Transient Jail Population. Open Forum Infect Dis.&nbsp;2017 Jul 7;4(3):ofx142.&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><strong>Akiyama MJ</strong>, Kaba F, Rosner Z, Alper H, Kopolow A, Litwin A, Venters H, Macdonald R. Correlates of Hepatitis C Virus Infection in the Targeted Testing Program of the New York City Jail System: Epidemiologic Patterns and Priorities for Action. Public Health Reports.&nbsp;2017 Jan/Feb;132(1):41-47.</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><strong>Akiyama MJ</strong>, Kaba F, Rosner Z, Alper H, Holzman RS, MacDonald R. Hepatitis C Screening of the &ldquo;Birth Cohort&rdquo; (b. 1945-1965) and younger inmates of New York City Jails.&nbsp;AJPH.&nbsp;2016 Jul;106(7):1276-7.</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">Feller DJ,&nbsp;<strong>Akiyama MJ</strong>, Gordon P, Agins BD. Readmissions in HIV-infected Inpatients: A Large Cohort Analysis.&nbsp;JAIDS.&nbsp;2016 Apr 1;71(4):407-12.</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">BardfieldJ, Agins B,&nbsp;<strong>Akiyama MJ</strong>, Mutandi G, Basenero A, Luphala P, Kaindjee-tjituka F, Natanael S, Hamunime N. A Quality Improvement Approach to Capacity Building in Low- and Middle-Income Countries: The case of HEALTHQUAL International. AIDS.&nbsp;2015 Jul;29 Suppl2:S179-86. &nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">Vo PK, Vutien P,&nbsp;<strong>Akiyama MJ</strong>, Vu VD, Ha NB, Piotrowski JI, Wantuck J, Roytman MM, Tsai N, Cheung R, Li J, Nguyen MH. Poor Sustained Virologic Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir. Digestive Diseases and Sciences 2015 Apr;60(4):1045-51.</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><strong>Akiyama MJ</strong>, Piotrowski JI, Roytman MM, Chan A, Hong LK, Huddleston L, Trujillo R, Tsai N. New Triple Therapy for Chronic Hepatitis C: Real Life Clinical Experience in a Community Setting. Hawaii Journal of&nbsp;Medicine and Public Health 2013 Sep;72(9 Suppl 4):6-13.&nbsp;</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: Calibri, sans-serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">&nbsp;</p>
</div>

EMR ID

78529

Is Open Scheduling

On